Background: Lung cancer is the leading cause of cancer death in the world. In advanced
NSCLC, chemotherapy is the standard treatment strategy, but it has unfavorable side effects …

Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor
receptor–tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib …

Background: Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth
factor receptor (EGFR), which had antitumor activity in patients with previously treated non …

Purpose: Gefitinib is an oral agent that inhibits the tyrosine kinase of the epidermal growth
factor receptor. In phase I trials gefitinib was well tolerated and antitumor activity was seen in …

Purpose The purpose of this study was to determine whether the addition of the epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca …

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …

Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …

Gefitinib (IressaTM), an orally-active tyrosine kinase inhibitor of the epidermal growth factor
receptor (EGFR), is the first approved molecular-targeted drug for the management of …

Gefitinib has shown activity in the treatment of non-small-cell lung cancer (NSCLC) patients
who failed previous platinum-based combination chemotherapy and/or taxane treatment …

Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …